<DOC>
	<DOCNO>NCT03009032</DOCNO>
	<brief_summary>Late diagnose HIV-infected subject show impaired immunological recovery result great risk clinical progression . Gut bacteria metabolism appear impact immune recovery HIV-infected subject , nutritional intervention prebiotics probiotic seem exert immunological effect , clinical implication key population remain unknown . This pilot multicenter randomize placebo-controlled , double blind clinical trial HIV-infected ART-naive subject &lt; 350 CD4 T cells/mm3 AIDS . Participants randomize ( 1:1 ) either synbiotic nutritional supplement PMT25341 placebo 48 week , combination first-line ART . Primary outcomes safety immunological recovery . Secondary outcome include change fecal microbiota structure plasma inflammatory marker .</brief_summary>
	<brief_title>Synbiotics Advanced HIV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>HIVinfected ARTnaive subject &lt; 350 CD4 T cells/mm3 AIDS Initiating ART firstline regimen recommend Spanish GESIDA National Guidelines Age &lt; 18 year Pregnancy Type 1 2 diabetes Endstage renal disease Lactose intolerance Use immunomodulatory drug Neutrophil count &lt; 750cells/uL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>immunologic recovery</keyword>
	<keyword>microbiota</keyword>
	<keyword>prebiotics</keyword>
	<keyword>probiotic</keyword>
	<keyword>synbiotics</keyword>
</DOC>